Lupin receives tentative USFDA approval for Sitagliptin Tablets
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Sitagliptin Tablets USP, 25 mg, 50 mg, and 100 mg are indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus
Lacosamide is indicated to treat partial-onset seizures
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Darunavir is a protease inhibitor antiviral medicine that prevents Human Immunodeficiency Virus (HIV-1) from multiplying in the body
Cyclophosphamide is a chemotherapy medication that slows the growth of cancer cell
The product will be manufactured at Lupin's Pithampur facility in India
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
The company makes its maiden entry into Azerbaijan’s pharmaceutical market
Subscribe To Our Newsletter & Stay Updated